Simvastatin and the RhoA blocker rhosin rescue neurites, mitochondria, lysosomes, cytokines, and death in familial-PD and isogenic PARK2-null iPSC dopamine neurons. RhoA inhibition moves mitophagy and autophagy markers toward better turnover. A 32-line RhoA-activity screen is started (abstract cuts off).
Mito.news · at a glance
Parkinson disease · mitophagy · therapeutics
Editorial signal profile from the abstract (importance score, mito keywords, dysfunction tags, evidence density, translational cues). Not a figure reproduced from the preprint PDF.
Finding. Simvastatin, acting at least through RhoA, puts familial-PD iPSC dopamine neurons back together. Schmidt, Meyer and colleagues see neurites, mitochondria, lysosomes, cytokines, and survival improve, copied by the RhoA inhibitor rhosin. Mitophagy and autophagy markers move toward turnover. They started a 32-line RhoA-activity screen; the abstract stops there.
Score 82. Statin, RhoA, mitochondria, PARK2. Medium confidence: truncated screen.
Free HTML is above. Bots pay for JSON at /api/v1/papers/10-64898-2026-08-26-747232. Optional wallet tester: MetaMask ($0.005).
Simvastatin attenuates disease phenotypes in human induced pluripotent stem cell models of familial Parkinson’s disease through RhoA inhibition
10.64898/2026.08.26.747232
Schmidt SI, Okarmus J, Ryding M, Skousen IK, Jensen NFB, Christensen EB, Winkelmann LS, Juhl AD, Klæbel M, Blaabjerg M, Freude K, Wüstner D, Wade-Martins R, Ryan B, Meyer M.
